GYRE THERAPEUTICS INC (GYRE) Stock Fundamental Analysis

NASDAQ:GYRE • US4037831033

8.28 USD
-0.14 (-1.66%)
At close: Feb 20, 2026
8.28 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Taking everything into account, GYRE scores 6 out of 10 in our fundamental rating. GYRE was compared to 521 industry peers in the Biotechnology industry. While GYRE has a great health rating, its profitability is only average at the moment. GYRE is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year GYRE was profitable.
  • GYRE had a positive operating cash flow in the past year.
  • GYRE had negative earnings in 4 of the past 5 years.
  • In the past 5 years GYRE reported 4 times negative operating cash flow.
GYRE Yearly Net Income VS EBIT VS OCF VS FCFGYRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

  • GYRE has a Return On Assets of 4.17%. This is amongst the best in the industry. GYRE outperforms 90.21% of its industry peers.
  • GYRE has a Return On Equity of 6.53%. This is amongst the best in the industry. GYRE outperforms 90.59% of its industry peers.
  • GYRE has a better Return On Invested Capital (6.46%) than 92.32% of its industry peers.
Industry RankSector Rank
ROA 4.17%
ROE 6.53%
ROIC 6.46%
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
GYRE Yearly ROA, ROE, ROICGYRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

  • GYRE has a Profit Margin of 6.20%. This is amongst the best in the industry. GYRE outperforms 89.83% of its industry peers.
  • The Operating Margin of GYRE (11.22%) is better than 91.75% of its industry peers.
  • GYRE has a Gross Margin of 95.48%. This is amongst the best in the industry. GYRE outperforms 95.97% of its industry peers.
Industry RankSector Rank
OM 11.22%
PM (TTM) 6.2%
GM 95.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GYRE Yearly Profit, Operating, Gross MarginsGYRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • GYRE has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for GYRE has been increased compared to 1 year ago.
  • GYRE has more shares outstanding than it did 5 years ago.
  • GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GYRE Yearly Shares OutstandingGYRE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
GYRE Yearly Total Debt VS Total AssetsGYRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 8.84 indicates that GYRE is not in any danger for bankruptcy at the moment.
  • GYRE's Altman-Z score of 8.84 is amongst the best of the industry. GYRE outperforms 80.42% of its industry peers.
  • There is no outstanding debt for GYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.84
ROIC/WACC0.74
WACC8.72%
GYRE Yearly LT Debt VS Equity VS FCFGYRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 6.19 indicates that GYRE has no problem at all paying its short term obligations.
  • GYRE's Current ratio of 6.19 is fine compared to the rest of the industry. GYRE outperforms 63.53% of its industry peers.
  • A Quick Ratio of 5.64 indicates that GYRE has no problem at all paying its short term obligations.
  • GYRE's Quick ratio of 5.64 is fine compared to the rest of the industry. GYRE outperforms 60.65% of its industry peers.
Industry RankSector Rank
Current Ratio 6.19
Quick Ratio 5.64
GYRE Yearly Current Assets VS Current LiabilitesGYRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 128.26% over the past year.
  • Looking at the last year, GYRE shows a very negative growth in Revenue. The Revenue has decreased by -43.94% in the last year.
  • Measured over the past years, GYRE shows a very strong growth in Revenue. The Revenue has been growing by 143.34% on average per year.
EPS 1Y (TTM)128.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.39%
Revenue 1Y (TTM)-43.94%
Revenue growth 3Y143.34%
Revenue growth 5YN/A
Sales Q2Q%19.92%

3.2 Future

  • Based on estimates for the next years, GYRE will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.75% on average per year.
  • The Revenue is expected to grow by 17.78% on average over the next years. This is quite good.
EPS Next Y-40.64%
EPS Next 2Y-22.25%
EPS Next 3Y-49.4%
EPS Next 5Y16.75%
Revenue Next Year-3.9%
Revenue Next 2Y10.17%
Revenue Next 3Y6.96%
Revenue Next 5Y17.78%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
GYRE Yearly Revenue VS EstimatesGYRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
GYRE Yearly EPS VS EstimatesGYRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 63.69, GYRE can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, GYRE is valued cheaper than 90.21% of the companies in the same industry.
  • GYRE's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.99.
  • The Price/Forward Earnings ratio is 43.49, which means the current valuation is very expensive for GYRE.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of GYRE indicates a rather cheap valuation: GYRE is cheaper than 91.17% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.02. GYRE is valued rather expensively when compared to this.
Industry RankSector Rank
PE 63.69
Fwd PE 43.49
GYRE Price Earnings VS Forward Price EarningsGYRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 91.36% of the companies in the same industry are more expensive than GYRE, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, GYRE is valued cheaply inside the industry as 89.44% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 557.87
EV/EBITDA 46.92
GYRE Per share dataGYRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • GYRE's earnings are expected to decrease with -49.40% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.25%
EPS Next 3Y-49.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for GYRE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GYRE THERAPEUTICS INC

NASDAQ:GYRE (2/20/2026, 8:00:01 PM)

After market: 8.28 0 (0%)

8.28

-0.14 (-1.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-18
Earnings (Next)05-07
Inst Owners3.45%
Inst Owner Change5.98%
Ins Owners7.06%
Ins Owner Change0%
Market Cap752.57M
Revenue(TTM)107.27M
Net Income(TTM)6.65M
Analysts84.44
Price Target18.36 (121.74%)
Short Float %12.12%
Short Ratio17.63
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)79.72%
Min EPS beat(2)-34.64%
Max EPS beat(2)194.08%
EPS beat(4)1
Avg EPS beat(4)13.67%
Min EPS beat(4)-102.82%
Max EPS beat(4)194.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.9%
Min Revenue beat(2)-14.79%
Max Revenue beat(2)-9.01%
Revenue beat(4)1
Avg Revenue beat(4)-7.84%
Min Revenue beat(4)-23.85%
Max Revenue beat(4)16.28%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.66%
EPS NY rev (1m)0%
EPS NY rev (3m)77.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.18%
Valuation
Industry RankSector Rank
PE 63.69
Fwd PE 43.49
P/S 7.02
P/FCF 557.87
P/OCF 194.11
P/B 7.38
P/tB 7.75
EV/EBITDA 46.92
EPS(TTM)0.13
EY1.57%
EPS(NY)0.19
Fwd EY2.3%
FCF(TTM)0.01
FCFY0.18%
OCF(TTM)0.04
OCFY0.52%
SpS1.18
BVpS1.12
TBVpS1.07
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.81
Profitability
Industry RankSector Rank
ROA 4.17%
ROE 6.53%
ROCE 8.39%
ROIC 6.46%
ROICexc 11.19%
ROICexgc 11.89%
OM 11.22%
PM (TTM) 6.2%
GM 95.48%
FCFM 1.26%
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 110.59%
Cap/Sales 2.36%
Interest Coverage 250
Cash Conversion 27.08%
Profit Quality 20.28%
Current Ratio 6.19
Quick Ratio 5.64
Altman-Z 8.84
F-Score5
WACC8.72%
ROIC/WACC0.74
Cap/Depr(3y)333.79%
Cap/Depr(5y)313.61%
Cap/Sales(3y)3.51%
Cap/Sales(5y)4.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)128.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.39%
EPS Next Y-40.64%
EPS Next 2Y-22.25%
EPS Next 3Y-49.4%
EPS Next 5Y16.75%
Revenue 1Y (TTM)-43.94%
Revenue growth 3Y143.34%
Revenue growth 5YN/A
Sales Q2Q%19.92%
Revenue Next Year-3.9%
Revenue Next 2Y10.17%
Revenue Next 3Y6.96%
Revenue Next 5Y17.78%
EBIT growth 1Y-72.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.41%
EBIT Next 3Y-66.98%
EBIT Next 5YN/A
FCF growth 1Y110.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y128.93%
OCF growth 3YN/A
OCF growth 5YN/A

GYRE THERAPEUTICS INC / GYRE FAQ

What is the fundamental rating for GYRE stock?

ChartMill assigns a fundamental rating of 6 / 10 to GYRE.


Can you provide the valuation status for GYRE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to GYRE THERAPEUTICS INC (GYRE). This can be considered as Fairly Valued.


Can you provide the profitability details for GYRE THERAPEUTICS INC?

GYRE THERAPEUTICS INC (GYRE) has a profitability rating of 5 / 10.


What is the valuation of GYRE THERAPEUTICS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for GYRE THERAPEUTICS INC (GYRE) is 63.69 and the Price/Book (PB) ratio is 7.38.


What is the earnings growth outlook for GYRE THERAPEUTICS INC?

The Earnings per Share (EPS) of GYRE THERAPEUTICS INC (GYRE) is expected to decline by -40.64% in the next year.